Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Synthesis and evaluation of 2'-dihalo ribonucleotide prodrugs with activity against hepatitis C virus.

Chris Krueger A, Chen HJ, Randolph JT, Brown BS, Halvorsen GT, Heyman HR, Li T, Marvin CC, Shanley JP, Voight EA, Bow DAJ, Van Handel C, Peterkin V, Carr RA, Stolarik D, Dekhtyar T, Irvin ML, Krishnan P, Henry RF, Wagner R, DeGoey DA.

Bioorg Med Chem. 2019 Nov 11:115208. doi: 10.1016/j.bmc.2019.115208. [Epub ahead of print]

PMID:
31740203
2.

Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir.

Schnell G, Krishnan P, Tripathi R, Beyer J, Reisch T, Irvin M, Dekhtyar T, Lu L, Ng TI, Xie W, Pilot-Matias T, Collins C.

PLoS One. 2018 Oct 4;13(10):e0205186. doi: 10.1371/journal.pone.0205186. eCollection 2018.

3.

Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection.

Ng TI, Pilot-Matias T, Tripathi R, Schnell G, Krishnan P, Reisch T, Beyer J, Dekhtyar T, Irvin M, Lu L, Asatryan A, Campbell A, Yao B, Lovell S, Mensa F, Lawitz EJ, Kort J, Collins C.

Viruses. 2018 Aug 28;10(9). pii: E462. doi: 10.3390/v10090462.

4.

Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials.

Krishnan P, Pilot-Matias T, Schnell G, Tripathi R, Ng TI, Reisch T, Beyer J, Dekhtyar T, Irvin M, Xie W, Larsen L, Mensa FJ, Collins C.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01249-18. doi: 10.1128/AAC.01249-18. Print 2018 Oct.

5.

Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530).

Wagner R, Randolph JT, Patel SV, Nelson L, Matulenko MA, Keddy R, Pratt JK, Liu D, Krueger AC, Donner PL, Hutchinson DK, Flentge C, Betebenner D, Rockway T, Maring CJ, Ng TI, Krishnan P, Pilot-Matias T, Collins C, Panchal N, Reisch T, Dekhtyar T, Mondal R, Stolarik DF, Gao Y, Gao W, Beno DA, Kati WM.

J Med Chem. 2018 May 10;61(9):4052-4066. doi: 10.1021/acs.jmedchem.8b00082. Epub 2018 Apr 23.

PMID:
29653491
6.

Characterization of demographics and NS5A genetic diversity for hepatitis C virus genotype 4-infected patients with or without cirrhosis treated with ombitasvir/paritaprevir/ritonavir.

Schnell G, Tripathi R, Beyer J, Reisch T, Krishnan P, Dekhtyar T, Irvin M, Hall C, Yu Y, Mobashery N, Redman R, Pilot-Matias T, Collins C.

J Viral Hepat. 2018 Sep;25(9):1078-1088. doi: 10.1111/jvh.12906. Epub 2018 May 8.

PMID:
29624809
7.

Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan.

Krishnan P, Schnell G, Tripathi R, Beyer J, Reisch T, Dekhtyar T, Irvin M, Xie W, Fu B, Burroughs M, Redman R, Kumada H, Chayama K, Collins C, Pilot-Matias T.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e02217-17. doi: 10.1128/AAC.02217-17. Print 2018 Feb.

8.

In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir.

Ng TI, Tripathi R, Reisch T, Lu L, Middleton T, Hopkins TA, Pithawalla R, Irvin M, Dekhtyar T, Krishnan P, Schnell G, Beyer J, McDaniel KF, Ma J, Wang G, Jiang LJ, Or YS, Kempf D, Pilot-Matias T, Collins C.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01620-17. doi: 10.1128/AAC.01620-17. Print 2018 Jan.

9.

Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir.

Schnell G, Tripathi R, Krishnan P, Beyer J, Reisch T, Irvin M, Dekhtyar T, Setze C, Rodrigues L Jr, Alves K, Burroughs M, Redman R, Chayama K, Kumada H, Collins C, Pilot-Matias T.

J Med Virol. 2018 Jan;90(1):109-119. doi: 10.1002/jmv.24923. Epub 2017 Sep 22.

10.

In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir.

Ng TI, Krishnan P, Pilot-Matias T, Kati W, Schnell G, Beyer J, Reisch T, Lu L, Dekhtyar T, Irvin M, Tripathi R, Maring C, Randolph JT, Wagner R, Collins C.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02558-16. doi: 10.1128/AAC.02558-16. Print 2017 May.

11.

Discovery of fluorobenzimidazole HCV NS5A inhibitors.

Randolph JT, Flentge CA, Donner P, Rockway TW, Patel SV, Nelson L, Hutchinson DK, Mondal R, Mistry N, Reisch T, Dekhtyar T, Krishnan P, Pilot-Matias T, Stolarik DF, Beno DWA, Wagner R, Maring C, Kati WM.

Bioorg Med Chem Lett. 2016 Nov 15;26(22):5462-5467. doi: 10.1016/j.bmcl.2016.10.030. Epub 2016 Oct 13.

PMID:
27780635
12.

Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir.

Schnell G, Tripathi R, Beyer J, Reisch T, Krishnan P, Lu L, Dekhtyar T, Hall C, Vilchez RA, Pilot-Matias T, Collins C.

Antimicrob Agents Chemother. 2015 Nov;59(11):6807-15. doi: 10.1128/AAC.01229-15. Epub 2015 Aug 17.

13.

In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450.

Pilot-Matias T, Tripathi R, Cohen D, Gaultier I, Dekhtyar T, Lu L, Reisch T, Irvin M, Hopkins T, Pithawalla R, Middleton T, Ng T, McDaniel K, Or YS, Menon R, Kempf D, Molla A, Collins C.

Antimicrob Agents Chemother. 2015 Feb;59(2):988-97. doi: 10.1128/AAC.04227-14. Epub 2014 Dec 1.

14.

P1-substituted symmetry-based human immunodeficiency virus protease inhibitors with potent antiviral activity against drug-resistant viruses.

Degoey DA, Grampovnik DJ, Chen HJ, Flosi WJ, Klein LL, Dekhtyar T, Stoll V, Mamo M, Molla A, Kempf DJ.

J Med Chem. 2011 Oct 27;54(20):7094-104. doi: 10.1021/jm201109t. Epub 2011 Sep 21.

PMID:
21899332
15.

2-Pyridyl P1'-substituted symmetry-based human immunodeficiency virus protease inhibitors (A-792611 and A-790742) with potential for convenient dosing and reduced side effects.

Degoey DA, Grampovnik DJ, Flentge CA, Flosi WJ, Chen HJ, Yeung CM, Randolph JT, Klein LL, Dekhtyar T, Colletti L, Marsh KC, Stoll V, Mamo M, Morfitt DC, Nguyen B, Schmidt JM, Swanson SJ, Mo H, Kati WM, Molla A, Kempf DJ.

J Med Chem. 2009 Apr 23;52(8):2571-86. doi: 10.1021/jm900044w.

PMID:
19323562
16.

Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742.

Dekhtyar T, Ng TI, Lu L, Masse S, DeGoey DA, Flosi WJ, Grampovnik DJ, Klein LL, Kempf DJ, Molla A.

Antimicrob Agents Chemother. 2008 Apr;52(4):1337-44. doi: 10.1128/AAC.01132-07. Epub 2008 Jan 22.

17.

A replicon-based shuttle vector system for assessing the phenotype of HCV NS5B polymerase genes isolated from patient populations.

Middleton T, He Y, Pilot-Matias T, Tripathi R, Lim BH, Roth A, Chen CM, Koev G, Ng TI, Krishnan P, Pithawalla R, Mondal R, Dekhtyar T, Lu L, Mo H, Kati WM, Molla A.

J Virol Methods. 2007 Nov;145(2):137-45. Epub 2007 Jun 29.

PMID:
17604129
18.

In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.

Masse S, Lu X, Dekhtyar T, Lu L, Koev G, Gao F, Mo H, Kempf D, Bernstein B, Hanna GJ, Molla A.

Antimicrob Agents Chemother. 2007 Sep;51(9):3075-80. Epub 2007 Jun 18.

19.

Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro.

Lu L, Dekhtyar T, Masse S, Pithawalla R, Krishnan P, He W, Ng T, Koev G, Stewart K, Larson D, Bosse T, Wagner R, Pilot-Matias T, Mo H, Molla A.

Antiviral Res. 2007 Oct;76(1):93-7. Epub 2007 May 22.

PMID:
17561278
20.

Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology.

Ng TI, Mo H, Pilot-Matias T, He Y, Koev G, Krishnan P, Mondal R, Pithawalla R, He W, Dekhtyar T, Packer J, Schurdak M, Molla A.

Hepatology. 2007 Jun;45(6):1413-21.

PMID:
17518369
21.
22.

Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro.

Koev G, Dekhtyar T, Han L, Yan P, Ng TI, Lin CT, Mo H, Molla A.

Antiviral Res. 2007 Jan;73(1):78-83. Epub 2006 Aug 17.

PMID:
16945431
23.

Discovery of imidazolidine-2,4-dione-linked HIV protease inhibitors with activity against lopinavir-resistant mutant HIV.

Flosi WJ, DeGoey DA, Grampovnik DJ, Chen HJ, Klein LL, Dekhtyar T, Masse S, Marsh KC, Mo HM, Kempf D.

Bioorg Med Chem. 2006 Oct 1;14(19):6695-712. Epub 2006 Jul 7.

PMID:
16828558
24.

Synthesis, antiviral activity, and pharmacokinetic evaluation of P3 pyridylmethyl analogs of oximinoarylsulfonyl HIV-1 protease inhibitors.

Randolph JT, Huang PP, Flosi WJ, DeGoey D, Klein LL, Yeung CM, Flentge C, Sun M, Zhao C, Dekhtyar T, Mo H, Colletti L, Kati W, Marsh KC, Molla A, Kempf DJ.

Bioorg Med Chem. 2006 Jun 15;14(12):4035-46. Epub 2006 Feb 28.

PMID:
16504523
25.

Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro.

Mo H, Lu L, Pilot-Matias T, Pithawalla R, Mondal R, Masse S, Dekhtyar T, Ng T, Koev G, Stoll V, Stewart KD, Pratt J, Donner P, Rockway T, Maring C, Molla A.

Antimicrob Agents Chemother. 2005 Oct;49(10):4305-14.

26.

Oximinoarylsulfonamides as potent HIV protease inhibitors.

Yeung CM, Klein LL, Flentge CA, Randolph JT, Zhao C, Sun M, Dekhtyar T, Stoll VS, Kempf DJ.

Bioorg Med Chem Lett. 2005 May 2;15(9):2275-8.

PMID:
15837308
27.

Conserved residues in the coiled-coil pocket of human immunodeficiency virus type 1 gp41 are essential for viral replication and interhelical interaction.

Mo H, Konstantinidis AK, Stewart KD, Dekhtyar T, Ng T, Swift K, Matayoshi ED, Kati W, Kohlbrenner W, Molla A.

Virology. 2004 Nov 24;329(2):319-27.

28.

Synthesis and antiviral activity of P1' arylsulfonamide azacyclic urea HIV protease inhibitors.

Huang PP, Randolph JT, Klein LL, Vasavanonda S, Dekhtyar T, Stoll VS, Kempf DJ.

Bioorg Med Chem Lett. 2004 Aug 2;14(15):4075-8.

PMID:
15225729
29.

Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir.

Mo H, Lu L, Dekhtyar T, Stewart KD, Sun E, Kempf DJ, Molla A.

Antiviral Res. 2003 Aug;59(3):173-80.

PMID:
12927307
30.

Design and synthesis of pseudo-symmetric HIV protease inhibitors containing a novel hydroxymethylcarbonyl (HMC)-hydrazide isostere.

Hidaka K, Kimura T, Hayashi Y, McDaniel KF, Dekhtyar T, Colletti L, Kiso Y.

Bioorg Med Chem Lett. 2003 Jan 6;13(1):93-6.

PMID:
12467624

Supplemental Content

Loading ...
Support Center